Got $1,000? 2 No-Brainer Stocks to Buy and Hold for at Least the Next DecadeThe Motley Fool • 11/06/22
Vertex to Present New Data on its Portfolio of Cystic Fibrosis Medicines at the 2022 North American Cystic Fibrosis ConferenceBusiness Wire • 11/03/22
This Bear Market Could Be the Best Investing Opportunity in More Than a DecadeThe Motley Fool • 10/29/22
Vertex Pharmaceuticals (VRTX) Q3 Earnings and Revenues Surpass EstimatesZacks Investment Research • 10/27/22
Vertex Pharmaceuticals Jumps After Quarterly Beat, Raises 2022 OutlookInvestors Business Daily • 10/27/22
Which Stocks Are Most Likely to Thrive in a Recession? Here's What History ShowsThe Motley Fool • 10/23/22
CRISPR Stocks: Will Concerns Over Risk Inhibit Gene-Editing Cures?Investors Business Daily • 10/20/22